Krystal Biotech, Inc.
KRYS
Hisse Senetlerindeki Sıralama
#2154
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Hisse Fiyatı
$320.50
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$9.49B
Değişim (1 gün)
1.24%
Değişim (1 yıl)
63.55%
Ülke
US
Ticaret Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Krystal Biotech, Inc. (KRYS) için temettü verimi geçmişi
Krystal Biotech, Inc. (hisse sembolü: KRYS) temettü verimi (TTM) 2023-12-31 itibariyle: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Krystal Biotech, Inc. (KRYS) için 2016 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
| Yıl | Temettü Verimi | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Benzer şirketler veya rakiplerin temettü verimi (TTM)
| Şirket | Temettü Verimi | Ülke |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
